Companies/US/ABBV

ABBVIE INC.

Income flow

Annual
ABBV 10-K Income StatementPeriod 2025-12-31Source 10-K
Skyrizi$18BRinvoq$8BHumira$5BBotox Therapeutic$4BVraylar$4BImbruvica$3BVenclexta$3BOther Products$3BBotox Cosmetic$3BMavyret$1BUbrelvy$1BOther Aesthetics$1BQulipta$1BOther Eye Care$1BJuvederm Collection$993MLinzess Constella$907MElahere$690MOzurdex$493MVyalev$482MLumigan Ganfort$410MDuodopa$381MEpkinly$271MOther Neuroscience$207MAlphagan Combigan$197MRevenue$61B+9% Y/YGross profit$43B+9% Y/YCost of revenue$18BOperating profit$15B+65% Y/YOperating expenses$28BNet profit$4B-1% Y/YTax$2BSG&A$14BR&D & other$14B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$59.6B
  • Skyrizi$17.6B29.5%
  • Rinvoq$8.3B13.9%
  • Humira$4.5B7.6%
  • Botox Therapeutic$3.8B6.3%
  • Vraylar$3.6B6.1%
  • Imbruvica$2.9B4.8%
  • Venclexta$2.8B4.7%
  • Other Products$2.6B4.4%
  • Botox Cosmetic$2.6B4.4%
  • Mavyret$1.3B2.2%
  • Ubrelvy$1.3B2.1%
  • Other Aesthetics$1.3B2.1%
  • Qulipta$1.0B1.7%
  • Other Eye Care$1.0B1.7%
  • Juvederm Collection$993M1.7%
  • Linzess Constella$907M1.5%
  • Elahere$690M1.2%
  • Ozurdex$493M0.8%
  • Vyalev$482M0.8%
  • Lumigan Ganfort$410M0.7%
  • Duodopa$381M0.6%
  • Epkinly$271M0.5%
  • Other Neuroscience$207M0.3%
  • Alphagan Combigan$197M0.3%
By geography
By geography$61.2B
  • United States$46.6B76.2%
  • Other countries$5.8B9.4%
  • DE$1.7B2.8%
  • JP$1.3B2.1%
  • CA$1.2B2.0%
  • CN$1.0B1.6%
  • FR$806M1.3%
  • GB$626M1.0%
  • ES$609M1.0%
  • IT$580M0.9%
  • BR$478M0.8%
  • AU$459M0.8%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).2.52%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.3.43%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).6.83PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.190.4%Shares outTotal shares currently outstanding (issued and not retired).1.77BFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).1.76B
Upcoming dividend
Next ex-div
2026-10-15 · declared
Next pay
2026-11-16
Last cash
1.73 · 2026-07-15

Valuation

Trailing PE 94.6 (2025-12-31)PE trend

Fiscal PE5

PeriodEPSClosePE
2025-12-312.36223.2194.6
2024-12-312.39167.7370.2
2023-12-312.72141.1251.9
2022-12-316.63141.4521.3
2021-12-316.45114.0717.7

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.